Seyed Mohammad Abedi
Overview
Explore the profile of Seyed Mohammad Abedi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abedi S, Ghadirzadeh E, Karimi H, Nezhadnaderi P, Daryabari S, Moradi A, et al.
Eur Heart J Imaging Methods Pract
. 2025 Jan;
3(1):qyae142.
PMID: 39811013
Aims: While most clinical guidelines recommend using a 64-projection view technique, some protocols do not specify a preference between 32-projection and 64-projection methods for conducting myocardial perfusion scintigraphy (MPS), which...
2.
Mardanshahi A, Vaseghi S, Hosseinimehr S, Abedi S, Molavipordanjani S
Ann Nucl Med
. 2023 Nov;
38(2):139-153.
PMID: 38032496
Background: The 5-hydroxytryptamine receptor (5-HTR) family includes seven classes of receptors. The 5-HTR is the newest member of this family and contributes to different physiological and pathological processes. As a...
3.
Farsavian A, Ghadirzadeh E, Yazdani Charati J, Rahmanzade H, Khalilizad M, Abedi S
Nucl Med Commun
. 2023 Jun;
44(8):697-702.
PMID: 37272296
Objective: In the management of ST-segment elevation myocardial infarction (STEMI), if the treatment has not been initiated within the first 24 h and the patient no longer exhibits any symptoms,...
4.
Molavipordanjani S, Mousavi T, Khorramimoghaddam A, Talebpour Amiri F, Abedi S, Hosseinimehr S
Ann Nucl Med
. 2023 Apr;
37(7):400-409.
PMID: 37115407
Background: Peptide receptor radionuclide therapy (PRRT) has evolved in cancer therapy and diagnosis. LTVSPWY, as a peptide, can target HER2 receptor; on the other hand, Lu emits β which is...
5.
Karimi M, Mardanshahi A, Irannejad H, Abedi S, Molavipordanjani S
Bioorg Chem
. 2023 Mar;
135:106486.
PMID: 36965286
Glioblastoma multiform (GBM) is one of the most aggressive tumors of the central nervous system in humans. GBM overexpresses serotonin-7 receptors (5-HTRs); hence, this study aims to develop 5-HTR targeted...
6.
Sadghian M, Mousavi S, Abedi S, JafariSarouei M, Gooran M, Balmeh P, et al.
Pediatr Surg Int
. 2023 Mar;
39(1):147.
PMID: 36879145
Background: Ureteropelvic junction obstruction is a relatively common urologic problem in children. Most cases present with pelvicaliceal dilatation in antenatal period. Historically most UPJO cases were treated with surgical procedures,...
7.
Biabani Ardakani J, Abedi S, Mardanshahi A, Shojaee L, Zaboli E, Khorramimoghaddam A, et al.
Clin Breast Cancer
. 2022 Dec;
23(2):219-230.
PMID: 36581518
Purpose: The accurate determination of human epidermal growth factor receptor 2 (HER2) status can predict response to treatment with HER2-targeted therapy for HER2-positive breast cancer patients. [Tc]Tc-HYNIC-(Ser)-LTVPWY ([Tc]Tc-HYNIC-LY) is a...
8.
Shahani S, Mehraban N, Talebpour Amiri F, Abedi S, Noaparast Z, Mohammadinia S
Ann Nucl Med
. 2022 Dec;
37(3):166-175.
PMID: 36469234
Objective: Hepatotoxicity remains amongst the restricting factors of Methotrexate (MTX)-associated cancer therapy, especially in high doses of chemo-drugs or prolonged treatment. Due to the known protective effects of Melissa officinalis ...
9.
Kaihani S, Sadeghzadeh N, Abediankenari S, Abedi S
Ann Nucl Med
. 2022 Oct;
37(1):70.
PMID: 36222996
No abstract available.
10.
Ebrahimi F, Noaparast Z, Abedi S, Hosseinimehr S
Med Oncol
. 2022 Sep;
39(12):204.
PMID: 36175805
We hypothesized that a novel design of the LTVPWY (LY) peptide might exhibit a great potential for improving binding affinity and targeting HER2-overexpressed tumors. Hence, new dimer construction of Tc-labeled...